Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Proactive: Hello, you’re watching Proactive. Joining me is Lisata Therapeutics Inc CEO Dr David Mazzo. David, very good to speak with you. Could you walk us through the revenue potential of the Catalent deal? Dr David Mazzo: ...